Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CHKA | P35790 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.45 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3828888 | 0.98 | CA2 (0.46) | CA2CA12CA1CA9CHKA | |
| SCHEMBL3100695 | 0.98 | CA2 (0.46) | CA2CA12CA1CA9CHKA | |
| Hydrochloric Acid SCHEMBL6898768 | 0.98 | CA2 (0.46) | CA2CA12CA1CA9CHKA | |
| SCHEMBL3827972 | 0.98 | CA2 (0.46) | CA2CA12CA1CA9CHKA | |
| Trifluoroacetic Acid SCHEMBL22233151 | 0.94 | PKM (0.47) | CA2CA12CA1CA9CHKA | |
| SCHEMBL28950008 | 0.92 | CA2 (0.50) | CA2CA12CA1CA9CHKA | |
| SCHEMBL14044902 | 0.90 | CA2 (0.48) | CA2CA12CA1CA9CHKA | |
| SCHEMBL29201246 | 0.90 | CA2 (0.41) | CA2CA12CA1CA9CHKA | |
| SCHEMBL3832932 | 0.88 | CA2 (0.47) | CA2CA12CA1CA9CHKA | |
| SCHEMBL3833764 | 0.88 | CA2 (0.47) | CA2CA12CA1CA9CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 411 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930957-A | Trifluoro acetyl piperazine modified polyarylpiperidine film, preparation method thereof and application thereof in neutral organic flow battery | 中盐金坛盐化有限责任公司 | 2025-05-06 | — | — | CN | claimed |
| EP-3489238-B1 | PHARMACEUTICAL COMPOSITIONS OF 6H-PYRIDO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-ONE AND [1,2,4]TRIAZOLO[1,5-C]PTERIDIN-5(6H)-ONE DERIVATIVES AS PDE1 INHIBITORS FOR TREATING E.G. NEUROLOGICAL DISORDERS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2021-10-13 | — | — | EP | claimed |
| EP-2861603-B1 | 6-Benzyl-6H-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and 6-benzyl-[1,2,4]triazolo[1,5-c]pteridin-5(6H)-one derivatives as PDE1 inhibitors for treating e.g. neurological disorders | DART NEUROSCIENCE CAYMAN LTD (KY) | 2018-12-19 | — | — | EP | claimed |
| EP-4735438-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
| CN-119930957-A | Trifluoro acetyl piperazine modified polyarylpiperidine film, preparation method thereof and application thereof in neutral organic flow battery | 中盐金坛盐化有限责任公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119930957-A | Trifluoro acetyl piperazine modified polyarylpiperidine film, preparation method thereof and application thereof in neutral organic flow battery | 中盐金坛盐化有限责任公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119930957-A | Trifluoro acetyl piperazine modified polyarylpiperidine film, preparation method thereof and application thereof in neutral organic flow battery | 中盐金坛盐化有限责任公司 | 2025-05-06 | — | — | CN | disclosed |
| US-12275727-B2 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | 280 BIO, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20250042889-A1 | 3CLPRO PROTEASE INHIBITOR | SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) | 2025-02-06 | — | — | US | disclosed |
| US-20250011291-A1 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| WO-2002034745-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-05-02 | — | — | WO | disclosed |
| US-6258360-B1 | BENZOATE CONJUGATES; ANTITUMOR AGENTS | IGEN INTERNATIONAL, INC. | 2001-07-10 | — | — | US | disclosed |
| CN-1065245-C | Substituted tetracyclic oxazepine and thiazepine derivatives having affinity for 5-HT2 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2001-05-02 | — | — | CN | disclosed |
| CN-1162313-A | Substituted tetracyclic azepine derivatives having affinity for 5-HT2 receptors | JANSSEN PHARMACEUTICA NV (BE) | 1997-10-15 | — | — | CN | disclosed |
| CN-1162314-A | Substituted tetraazazepine * and thiaza * derivatives having affinity for the 5-HT2 receptor | JANSSEN PHARMACEUTICA NV (BE) | 1997-10-15 | — | — | CN | disclosed |
| EP-0746336-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0746336-A4 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN INC (US) | 1996-07-26 | — | — | EP | disclosed |
| WO-1993002703-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1993-02-18 | — | — | WO | disclosed |
| US-4416884-A | ANTIBIOTIC, BACTERICIDE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275727-B2 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | PARG, CYP3A5, CYP11B1 | CA2 4434/4885CA12 4152/4885CA1 4642/4885 |
| US-20250042889-A1 | 3CLPRO PROTEASE INHIBITOR | ACE, ACE2, CTRL | CA2 1890/4885CA12 2134/4885CA1 1802/4885 |
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | CA2 4203/4885CA12 4358/4885CA1 4296/4885 |
| US-20250011291-A1 | KEAP1 INHIBITORS AND USES THEREOF | KEAP1, NFE2L2, NQO1 | CA2 4545/4885CA12 4863/4885CA1 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.